Cytokinetics Incorporated Price to Cash Flow Ratio (PCF) Ratios, (CYTK) Valuation Ranking and Trends, Fundamental Ratios

CYTK Price to Cash Flow Ratio	(Sep 30 2025)	(Jun 30 2025)	(Mar 31 2025)	(Dec 31 2024)	(Sep 30 2024)
Cash Flow Trailing 12 Months	III. Quarter	II. Quarter	I. Quarter	IV. Quarter	III. Quarter
Price to Cash Flow (TTM) Ratio	current 39.72	39.72	39.72	39.72	39.72
Cash flow TTM Y / Y Change	- %	- %	- %	- %	- %
Cash flow Y / Y Change	- %	-96.44 %	- %	259.8 %	- %
Stock performance	to date 63.61 %	-12.3 %	-11.61 %	-4.55 %	-11.93 %

Price to Cash Flow ratio Comment

Due to increase in Cash flow in III. Quarter, Cytokinetics Incorporated's current Price to Cash Flow ratio is at 39.72.

What is Price to Cash Flow Ratio?
Valuation in Major Pharmaceutical Preparations Industry

Price to Cash Flow ratio Company Ranking
Within:	No.
Industry	#164
Sector	#291
S&P 500	#1251

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.